Antibiotics, prescribed for outpatients in Sweden (ATC group J01 Excluding methenamine), DDD/1000/day, 1974-2002.

Antibiotics, different ages, 1990-2002, outpatients in Sweden (ATC J01 excl methenamine), DDD/1000/day

Norfloxacin and ciprofloxacin, women, all ages in Sweden, 1998 and 2002.

Norfloxacin and ciprofloxacin, men, all ages in Sweden, 1998 and 2002.

Antibiotics, prescribed for outpatients, Swedish counties (ATC group J01 excluding methenamine), DDD/1000/day, 1997 and 2002

Antibiotics (ATC group J01 excluding methenamine), age group 0-6 years, ten municipalities in Sweden with the highest and lowest consumption, 1998 and 2002.

Antibiotics (ATC grop J01 excluding methenamine), age group 80 years and older, ten municipalities in Sweden with the highest and lowest consumption, 1998 and 2002

Antibiotic consumption (ATC group J01 excluding methenamine) in hospital care, Sweden, 1985-2002

Antibiotic sales (ATC group J01 excluding methenamine) hospital care 1998 and 2002 in Sweden, expressed as DDD/1000/day and DDD/NA

Antifungals for gynaecological use (G01AF), prescriptions and OTC sale.

Antimycotics for systemic use (J02A), hospital-care 1985-2002 Sweden

PRP proportion (percent PRP out of all isolated pneumococci) per county and year

Age-adjusted PRP incidence during 1997-2002

Proportion (%) of PRP out of all pneumococcal isolates

National PRP incidence with and without Skåne county included

Overall national resistance rates (resistance isolates in percent of all pneumococcal isolates) for four different antibiotics 1994-2002 (data from the annual RSQC-programme, approximately 3000 isolates per year)

Age adjusted incidence of MRSA (n = 442)

Percentage colonized and infected MRSA cases 2002 (n = 442)

Reported origin of MRSA 2002 (n = 442)

Reported place of acquisition for domestic MRSA-cases (N = 305)

Reported way of domestic health care related acquisition (N = 186)

MRSA in Europe 2002. Data from EARSS (www.ears.rivm.nl 2003-04-06)

Reported VRE cases by county 2000-2002 (counties not in the graph did not report any case)

Reported VRE cases 2000-2002; age adjusted incidence

Streptococcus pyogenes in Sweden

Resistance rates (resistant isolates in percent of all Escherichia coli isolates for six different antibiotics 1996-2002. *Between 1996-2001 quinoloneresistance was tested with Norfloxacin, from 2002 tested with Nalidixic acid.

Resistance rates (% R and I) to fluoroquinolones in Escherichia coli in Europe 2002 (data from EARSS)

Tuberculosis in Sweden 1991-2002 Tuberculosis in Sweden 1991-2002. Number of cases confirmed by culture and number of whom with reported drug resistance

Annual number of cases with MDR-TB related to national origin

Use of antibiotics and diagnostics in respiratory tract infections Use of antibiotics and diagnostics in respiratory tract infections. The number of cases per diagnosis, the number of these receiving an antibitic and the number of cases where any diagnostics were used

The pattern of antibiotics for some of the respiratory tract infections in the 2002 STRAMA Diagnosis-antibiotic prescribing study

The pattern of antibiotics for urinary tract infections in the 2000 and 2002 STRAMA Diagnosis-antibiotic prescribing study